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Abstract
Major depressive disorder is one of the most prevalent psychological disorders within the
global population and has been for many years. Over the years, numerous interventions have
been developed to treat major depressive disorder, including cognitive-behavioral therapy. One
form of cognitive-behavioral therapy for depression, known as behavioral activation, focuses on
increasing contact with pleasant activities that are reinforcing. Many modifications of behavioral
activation have been made over the years, including the version Martell and colleagues (2010)
created which modified the traditional approach by decreasing the number of sessions. This new
approach, known as brief behavioral activation, also asks clients to clarify their values and then
schedule activities in line with these values. The present paper reviews the existing literature on
behavioral activation with and without a values component. The literature suggests that
behavioral activation with a values component was as successful at reducing depressive
symptoms as traditional behavioral activation, often with larger effect sizes overall than
traditional behavioral activation.
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Introduction
Mental health concerns are a serious and growing issue throughout the United States. In
2021, almost 20% of U.S. citizens experienced symptoms that met criteria for a mental illness
(Mental Health National, 2021). One of the most prevalent disorders in the U.S. population is
major depressive disorder (MDD). MDD has been defined in the Diagnostic and Statistical
Manual of Mental Disorders (DSM; American Psychiatric Association, 2013) since the first
published version of the DSM. The fifth edition of the manual with text revisions, DSM-5-TR,
characterizes MDD as having the hallmark symptoms of prolonged depressed mood and
diminished interest in previously pleasurable activities. Other problems that are associated with
the disorder include fatigue, sleep trouble, suicidal ideation, and feelings of guilt and
hopelessness (APA, 2013). MDD is also associated with diminished motivation to try out
experiences that may be rewarding (Sweet et al., 2021).
According to the National Institute of Mental Health, more than 20 million adults said
they experienced at least one depressive episode in the year 2020 (NIMH, 2022). For over 15
years, depression has been the leading cause of disability in the U.S. for individuals aged 15-45
(ADAA, 2021; NIMH, 2022). Studies have shown that MDD is associated with having
difficulties in social situations and having a negative orientation towards life and problems that
may arise (Klein et al., 2011). Because of the prevalence of MDD, and the impairment associated
with it, the identification and implementation of effective treatments is important.
There have been multiple interventions designed to treat clinical depression that have
been demonstrated to be effective at reducing function impairing symptoms. These interventions
can be divided into two broad categories: psychotherapy and pharmacotherapy. Psychotherapy is
a general term used to describe any therapy that treats mental health issues by bringing attention
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to the client’s mood, behaviors, thoughts, and feelings, followed by the teaching and
development of skills necessary to work through their struggles (Klein et al., 2011).
Pharmacotherapy for MDD involves the use of medication, typically antidepressants, to treat
mental health issues (Naguy, 2016). Psychotherapy and pharmacotherapy have both been
empirically supported as successful treatments for MDD. Cognitive therapy is a form of
psychotherapy that teaches clients to identify and challenge negative thinking patterns that
contribute to feelings of depression in hopes of alleviating symptoms (Otte et al., 2016).
Components of cognitive therapy have been combined with components of behavioral
therapy to create what is known as cognitive-behavioral therapy (CBT). This therapy focuses on
changing a patient’s cognition with the goal of it leading to positive changes in emotion and
behavior (Blackburn, 1981). A specific component of CBT that is used to increase patient’s
positive experiences in their life is known as behavioral activation (BA; Lejuez et al., 2011). BA
was initially developed with the belief that depressed individuals withdraw or even avoid
naturally reinforcing activities, which then leads to feelings of a depressed mood. The goal of
BA is to create behavioral changes that increase the amount of positive reinforcement received
on a day-to-day basis (Jacob et al., 2011). This teaches people with depression that contacting
pleasant activities throughout the day and week will lead to improvements in mood, and that this
is a more effective strategy than waiting for their mood to improve on its own before they engage
in activities.
The first time that this approach was discussed dates back to 1976, when Peter
Lewinsohn created a compressive treatment manual that focused on activity scheduling to
determine what behaviors a person found reinforcing coupled with social skill training (Kanter et
al., 2010). Other aspects of this approach included scheduling times during the day to do the
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specified activities while tracking their mood throughout their participation in the activity. Many
researchers and clinicians used the manual as a basis to create new treatment plans and form
research questions.
Martell and colleagues later developed a brief BA treatment for depression (BATD;
Kanter et al., 2010; Martell et al., 2010). Brief Behavioral Activation for Depression (BATD)
was originally designed for those in treatment for MDD who would benefit from a more
straightforward version of therapy to treat less complex depression or less intensive depressive
symptoms (Lejuez et al., 2011). Essentially, the only difference between traditional BA and
BATD is the number of sessions required and the individualized values approach BATD takes by
having clients focus on activity scheduling within a values-driven framework (Lejuez et al.,
2011). Adding the values component to BA allows the person in treatment to evaluate what is
most meaningful to them in their lives and then take steps to live in accordance with those
values. By adding this component to BA, clients are encouraged to take progressive steps
towards living a meaningful life while also achieving treatment goals (Jakupcak et al., 2020).
Clarifying values is accomplished through a collaborative process between client and therapist
where the client is tasked with evaluating certain life areas (e.g., relationships, education/career,
recreation/interests, mind/body/spirit, and daily responsibilities) to determine which aspects are
most important to them (Lejuez et al., 2011). Using a values-component with treatment helps the
client recognize what activities are in line with the person they want to be which can then be
incorporated into daily activity scheduling.
Both BA with a values component and traditional BA have been independently tested and
found to effectively decrease depressive symptoms. The different forms of the therapy have not
been compared against one another to see if one version has more success at reducing symptoms
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than the other. The purpose of the current paper is to review literature on BA with and without a
values component in order to inform future research.
Methods
Search Strategy
The author identified English language studies by searching the database PsychINFO.
The search terms utilized are as follows: “behavioral activation”, “major depressive disorder”,
“MDD”, “activity scheduling”, “values”, “depressive symptoms”, “depression.” All searches
included “AND” search terms. Publications were limited to clinical trials, component studies and
analog studies.
Inclusion Criteria
Studies were divided into two groups for ease of comparison. Studies that involved
behavioral activation with a values component group were included if they met the following
criteria: a) the article was peer-reviewed; b) participants were above the age of 18 years old; c)
participants were diagnosed with major depressive disorder (MDD) or subthreshold depressive
symptoms; d) the article included behavioral activation as a treatment; e) the treatment was
implemented by professionals or professionals in training; and e) the therapy included a values
component.
Studies that involved traditional behavioral activation were included if they met the
following criteria: a) the article was peer-reviewed; b) participants were above the age of 18
years old; c) participants were diagnosed with major depressive disorder (MDD) or subthreshold
depressive symptoms; d) the article included behavioral activation as a treatment; and e) the
treatment was implemented by professionals or professionals in training. One reviewer applied
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these criteria to all abstracts and full-text articles to determine if the articles met inclusion criteria
for this review.
Data Extraction
The data extracted from all articles included: treatment setting, number of participants,
age of participants, pre-screening/baseline measures, treatment design, outcome measures, and
the effect size. The effect size of each intervention was determined by comparing baseline scores
to post-intervention scores of specific scales used to measure depressive symptoms such as
Beck’s Depression Inventory-II (BDI-II; Beck et al., 1996).
Results
Literature Search
The initial search using the search terms described above identified 136 articles. After
excluding duplicates (n=16), there were 120 articles that remained. Of the 120 articles, 18 (15%)
were excluded because BA was not the main therapeutic intervention, 65 (54.1%) were excluded
because they used the BA scale but no direct BA intervention, 17 (14.2%) were excluded
because they were single case designs, 5 (4.2%) were excluded because they were reviews, 4
(3.3%) were excluded because a professional/in-training professional was not administering
treatment and 1 (0.8%) was excluded because it was not an adult population. Among the 10
articles retained, 5 used BA with a values-based framework and 5 used traditional BA.
Description of Studies
The ten studies that were identified used one of three designs: randomized controlled trial
(RCT), open trial, or prospective-quasi-experimental. Seven studies (i.e., Crits-Christoph et al.,
2021; Hopko et al., 2013; McIndoo et al., 2016; Moradveisi, et al., 2013; Okajima & Chen, 2017;
Pellas et al., 2021; Toghyani et al., 2018) used a RCT. Two studies (i.e., Acierno et al., 2012;
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Walsh et al., 2016) used an open trial design. And one study (i.e., Estupina Puig & Labrador
Encinas, 2012) used a prospective quasi-experimental design. Amongst all ten of the studies,
only three had a control group apart of their intervention (Crits-Christoph et al., 2021; Pellas et
al., 2021; Walsh et al., 2016).
Four of the studies (40%) used the DSM (American Psychiatric Association, 2013) at the
time of the study to define depression or MDD (Walsh et al., 2019; Acierno et al., 2012;
Moradveisi et al., 2014; Estupina Puig & Labrador Encinas, 2012). One study used BDI-II (Beck
et al., 1996) scores to determine if a participant was qualified to participate rather than the DSM
diagnostic criteria (McIndoo et al., 2016). Other depression scales were used as a prescreening to
determine eligibility and to measure participants’ baseline depressive symptoms including the
Harvard Department of Psychiatry/NDSD scale (HANDS; Hopko et al., 2013; Baer et al., 2000)
and the Quick Inventory of Depressive Symptomatology (QIDS; Crits-Christoph et al., 2021;
Rush et al., 1996). One of the studies used questions from multiple scales as a prescreening and
baseline measurement (Pellas et al., 2021). The scales used included the Montgomery and
Åsberg Depression Rating Scale (MADRS-S; Ntini et al., 2020), Geriatric Depression Rating
Scale-15 (GDRS-15; Greenberg, 2007), and the Patient Health Questionnaire (PHQ-9; Kroenke
et al., 2001). One of the studies used the Penn State Worry Questionnaire (PSWQ; Meyer et al.,
1990) as a prescreening to determine eligibility. The scale focuses on worry because this study
defined clinical excessive worry as a transdiagnostic process across both anxiety and depression
(Okajima & Chen, 2017).
When recruiting participants, almost all studies used multiple methods to advertise their
study. The methods that were used include online advertisements (n=4, 40%), flyers and
brochures (n=5, 50%), referrals from professionals (n=3, 30%), recruitment of current or past
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patients (n=4, 33%), offered as an option to those seeking treatment for MDD (n=3, 30%), and/or
community recruitment (n=2, 20%). One article did not specify their recruitment techniques.
The current articles being reviewed used some form of BA as their treatment
intervention. Three of the studies (Crits-Christoph et al., 2021; Estupina Puig & Labrador
Encinas, 2012; Moradveisi, et al., 2013) modeled their intervention off the traditional manual for
BA while only changing the number of sessions offered. Two other studies used modified
versions of the traditional standards of BA, one of which focused on worrying (BAW; Okajima
& Chen, 2017) and the other focused on therapeutic exposure (BA-TE; Acierno et al., 2012).
Four of the studies (Hopko et al., 2013; McIndoo et al., 2016; Toghyani et al., 2018; Walsh et al.,
2019) modeled their intervention off the brief BATD while only altering the number of sessions
offered. The final study used a specialized version of BATD for those in primary care (BA-PC;
Pellas et al., 2021).
Descriptions of treatment settings, interventions, outcome measures, and effect sizes of
the studies are included in Tables 1 and 2.
Behavioral Activation with a Values Component Effect Sizes
All ten of the studies that were included determined that BA had statistically significant
effect sizes. Of the five studies that used BA with a values component, two studies used control
groups and three studies tested BA with values against another intervention. The first study with
a control group (i.e., Walsh et al., 2019) used a between-group open trial design to determine
how effective BATD was at reducing depressive symptoms. Their intervention produced
medium effect sizes (d = 0.49; d = 0.43; p-value<0.05). The second study with a control group
(i.e., Pellas et al., 2021) used a between-group RCT study design to determine how effective
their intervention was at reducing depressive symptoms. Their intervention produced overall
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large effect sizes (d = 0.85; d = 0.69; d = 0.58; d = 0.63; d = 1.08; d =0.81; d = 0.28; pvalue<0.001).
The other three studies were tested against therapies such as problem-solving therapy
(PST), mindfulness-based therapy (MBT), and Islamic Lifestyle Psychoeducation Intervention
(ILPI). The study that tested the PST intervention against BATD (i.e., Hopko et al., 2013) found
that the PST was more effective at reducing depressive symptoms than BATD, but BATD still
produced medium effect sizes (d = 1.11; d = 0.41; d = 0.52; p-value<0.001). The study that
tested the BATD intervention against the MBT intervention (i.e., McIndoo et al., 2016) found
that both interventions produced overall large effect sizes, but BATD produced larger effects (d
= 0.77; d = 1.14; d = 0.77; d = 0.93; d = 0.23; d = 0.19; p-value<0.05). The study that tested the
ILPI intervention against the BATD intervention (i.e., Toghyani et al., 2018) determined that
both produced medium effect sizes, but the effect sizes of BA were larger (d = 0.73; d = 0.53; d
= 0.56; p-value<0.05).
Traditional Behavioral Activation Effect Sizes
All five studies that used an intervention modeled off of traditional BA were successful at
reducing depressive symptoms. Three of the studies used a RCT design and two of these studies
tested their BA intervention with a control group. One study that tested their BA intervention
against a control group (i.e., Crits-Christoph et al., 2021) produced small effect sizes (d = 0.35; d
= -0.49; d = -0.27; p-value<0.001). The other study that tested their BA intervention against a
control group (i.e., Okajima & Chen, 2017) produced large effect sizes (d = 0.74; p-value<0.01).
The other RCT study (i.e., Moradveisi et al., 2013) tested their BA intervention against an
antidepressant medication intervention to conclude which was more successful at reducing
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depressive symptoms. They determined that the BA intervention was successful at reducing
depressive symptoms and it produced a large effect size (d = 0.74; p-value<0.01).
The other two study designs included an open trial and a prospective quasi-experimental
design. The open trial (Acierno et al., 2012) consisted of a pilot trial testing their modified
version of BA with a focus on therapeutic exposure (BA-TE). Their intervention produced
medium effect sizes (d = 0.46; d = 0.41; d = 0.38; d = 0.27; d = 0.17; p-value<0.05). The
prospective quasi-experimental design (i.e., Estupina Puig & Labrador Encinas, 2012) tested BA
against multiple interventions including cognitive therapy (CT), interpersonal therapy (IT), and a
clinic intervention that used methods from BA, CT, and IT. This study discovered that their
clinic intervention was most successful, but BA still produced large effect sizes (d = 2.78).
Discussion
The current review reveals that behavioral activation with a values component may be as
successful as traditional behavioral activation at reducing depressive symptoms in people
diagnosed with major depressive disorder, or those with subthreshold symptoms. Additionally,
BA with a values component had larger effects sizes than traditional BA. Although more
research is required, the larger effect sizes may potentially indicate that BA with a values
component is more successful than traditional BA. Knowing this information is important for
MDD treatment because the differences in effect sizes suggest that the relatively simple addition
of a values component could improve the effectiveness of BA treatment for MDD. A randomized
control trial that focuses on BA with values versus traditional BA would help to determine which
is more efficacious and has the largest treatment effects.
As previously mentioned, MDD is the leading cause of disability in the U.S. for those
aged 15 to 45 years old and has been for years (ADAA, 2021; NIMH, 2022). The prevalence of
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this disorder is not just bad for those experiencing it, but also for the community, as it has lasting
impacts. Because so many people are experiencing disabling depression, it is costly for taxpayers
and will continue to be costly until an efficent treatment is in place to treat this group of people.
MDD is a disorder that can be treated, so finding the most effective treatment is important for all
of society.
Those with MDD can suffer through a plethora of symptoms that have negative effects on
the person’s cognition. These symptoms range from prolonged depressed mood, diminished
interest in previously pleasurable activities, fatigue, sleep trouble, suicidal ideation, and feelings
of guilt and hopelessness (American Psychiatric Association, 2013). Having a large range of
symptoms means that there is a range of experienced depression. Those who suffer with more
symptoms experience more intense depression compared to someone who suffers with less
symptoms. Because of this, learning which therapy is more effective is important for society and
for those suffering. A person with MDD feels better when they are experiencing fewer
depressive symptoms. Therapy is not always capable of completely removing experienced
symptoms, so finding the therapy that reduces the symptoms the most means a person with MDD
will know which therapy will help them feel the best. The findings from this review suggest that
BA with a values component is more effective at reducing depressive symptoms. This is
important for the mental health field because it potentially means that BA with a values
component should replace traditional BA when treating someone with MDD.
There are no studies that directly compared BA with a values aspect and traditional BA,
so future researchers should complete a randomized control trial directly comparing the
traditional BA intervention to the BA with a values component intervention. Future researchers
should also study the duration of time it takes for a patient to experience meaningful reductions
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of depressive symptoms with each therapy. Learning which specific therapy is the most effective
in terms of reducing experienced symptoms in the quickest amount of time is meaningful for
many reasons. From the patient’s perspective, finding out this information is important because it
directly translates to how quickly and effectively, they will notice improvements. From a
financial perspective, the quicker that symptoms are reduced the fewer therapy sessions a patient
would need to attend. Therapy sessions can be expensive, so the fewer number of sessions makes
therapy more financially obtainable to the general public. This information is important for the
greater community to learn as well because taxpayers are often the direct financers of public
services such as disability. Some disabilities are lifelong without the chance of improvement.
MDD is a disability that can improve with adequate treatment. Therefore, more research is
needed to learn how to treat the disorder most efficiently.
There are a few limitations to this review. Some of the studies lacked descriptive and
follow up data that may have been important to know. Another limitation to this review is that it
is not empirical. Analyzing the data extracted from the reviewed articles will demonstrate if BA
with a values component truly is more effective at reducing depressive symptoms.
Of all the included literature, the participants and research settings were inconsistent
between one another making the findings from this review inconsistent within each population of
people. Some studies had as few as 24 participants while others had much larger groups. Having
few participants makes the findings less generalizable to the general population. The participants
from some studies were not excluded if they had a comorbid disorder with MDD while there
were also studies that excluded participants if they had any other disorders or symptoms of
disorders. Some of the studies’ main focus was using BA to treat MDD with a comorbid disorder
such as psychosis, anxiety, PTSD, and substance abuse. Having comorbid disorders can have an
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influence on treatment success if the treatment is for a specific disorder. However, MDD tends to
have a high comorbidity rate so it would be appropriate for interventions to adjust for other
experienced symptoms.
This review suggests that behavioral activation with a values component has larger effect
sizes than traditional behavioral activation at reducing symptoms of major depressive disorder.
The larger effect sizes seen in behavioral activation with a values component could mean that it
has larger treatment effects than traditional behavioral activation. This conclusion is limited by
the fact that there is no research comparing the different models of behavioral activation directly.
It is important to learn which is the more effective version of the therapy to inform therapists and
clinicians on the best way to treat their clients.
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Table 1
Description of Studies - Behavioral Activation with a Values Component
Source/year
Walsh et
al., 2019

Hopko et
al., 2013

Treatment
Setting
Psychological
service centers
of Duke
University &
University of
North Carolina
– Chapel Hill

University of
Tennessee
Medical
Center’s
Cancer
Institute

Participants
33
outpatients
with MDD
(29% male,
mean=31)

Age
2045

Participants
completed an
MRI scan &
imaging
protocol.

20
nondepressed
controls
(30% male,
mean=31)
80 adults
with breast
cancer &
principal
diagnosis of
MDD

Pre-Treatment
Details
Experimental
group met
criteria for
DSM-IV-TR.

1868

Participants
scored a 9 or
higher from the
HANDS and
were
administered
ADIS-IV.

Treatment Details
Control group vs.
BATD
Up to 15 sessions of
BATD (average 11.67;
range 2-15).

Outcome
Measures
Measured
using BDI
and section
breakdown
from scale

Effect Size
BDI: 0.49
BDI anhedonia:
0.43
p-value<0.05

Completed positive
emotional regulation
task during fMRI.

BATD vs. PST
BATD along with
establishing patient
rapport, motivational
exercise,
depression/breast
cancer
psychoeducation &
intro of treatment
rationale.
PST goal is to increase
understanding

Measured
using CESD,
BDI-II &
HRSD

CESD Effect Size
BATD: 1.11
PST: 1.20
BDI-II Effect Size
BATD: 0.41
PST: 0.54
HRSD Effect Size
BATD: 0.52
PST: 0.80
p-value<0.001
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connection between
depression and
everyday problems,
increase ability to
accurately define
problems, learn
specific problemsolving skills & create
more positive
experiences through
improved problemsolving.

McIndoo et
al., 2016

University of
Tennessee

50 college
18students
21
(19 male, 31
female) with
significant
depression or
MDD

Pre-screened
for depression
using BDI-II &
ADIS-IV.
Also assessed
for current
engagement in
mindfulness
practices.

BA vs. MBT
Modeled after BATD:
Reduced to 4 sessions
& removed life value
assessment areas such
as employment and
political activities.
Focused on
mindfulness
meditation and other
activities.
MBT was modeled
after MBSR program.

Measured
using BDI-II,
HRSD, PSS,
RRS, FFMQ
& BAI

BA Effect Sizes
BDI-II: 0.77
HRSD: 1.14
PSS: 0.77
RRS: 0.93
FFMQ: 0.23
BAI: 0.19
MBT Effect Sizes
BDI-II: 0.68
HRSD: 1.03
PSS: 0.60
RRS: 0.87
FFMQ: 0.68
BAI: 0.32
p-value<0.05
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et al., 2018

Isfahan
psychological
service centers

24 patients
with MDD

2050

22
Participants had
to be diagnosed
with MDD
using the DSMV.
Also used BDIII for
assessment of
current
symptoms.

ILPI vs. BA
The ILPI was 10
sessions that focused
on healthy lifestyle
based on Islamic
teaching. Specifically
on the importance of
life balance,
nutritional education,
physical exercise,
sleep hygiene,
religious involvement,
social interactions,
recreation activities &
relapse prevention (if
applicable).

Measured
using BDI-II,
BHS &
PSWQ

ILPI Effect Sizes
BDI-II: 0.54
BHS: 0.43
PWSQ: 0.35

ILQ also
used for ILPI
group

BA Effect Sizes
BDI-II: 0.73
BHS: 0.53
PWSQ: 0.56
p-value<0.05

The BA therapy was 8
sessions of group
therapy based off
BATD.
Pellas et
al., 2021

Vastmandland, 41
Sweden
participants
with
At home
clinically
intervention
significant
symptoms of
MDD

65+

Participants
needed to score
a 12 or higher
on MADRS-S
and/or score a 9
or higher on
PHQ-9 and/or
score a 5 on
GDS-15.

Control group vs.
BATD
Treatment was
modeled after BATD
and occurred over a 4week period.
Also includes a mental
imagery component.

Measured
using
MADRS-S,
GDS-15,
PHQ-9,
GAD-7,
BADS-SF,
Psi-Q &
WHODAS12

Treatment Effect
Size
MADRS-S: 0.85
GDS-15: 0.69
PHQ-9: 0.58
GAD-7: 0.63
BADS-SF: 1.08
Psi-Q: 0.81
WHODAS-12:
0.28
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Also used
MINI
structured
clinical
interviews to
assesses
psychiatric
disorders.

p-value<0.001

Note. Summaries of studies that used behavioral activation with a values component including the treatment setting, the participant
descriptions, the baseline and pre-screening measures, the treatment details, the outcome measures, and the effect size. Effect sizes
were determined by comparing pre-treatment and post-treatment scores.

Abbreviations: DSM-IV-TR = Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision; MDD = Major
Depressive Disorder, BATD = Brief Behavioral Activation for Depression; BDI/BDI-II = Beck’s Depression Inventory; HANDS =
Harvard Department of Psychiatry/NDSD scale; ADIS-IV = Anxiety Disorders Interview Schedule, fourth edition; PST = Problemsolving Therapy; CESD = Center for Epidemiological Studies Depression; HRSD = Hamilton Depression Rating Scale; MBT =
Mindfulness-based Therapy; MBSR = Mindfulness Based Stress Reduction; PSS = Perceived Stress Scale; RRS = Rumination
Response Scale; FFMQ = Five Facet Mindfulness Questionnaire; BAI = Beck’s Anxiety Inventory; ILPI = Islamic Lifestyle
Psychoeducational Intervention; BHS = Beck’s Hopeless Scale; PSWQ = Penn State Worry Questionnaire; ILQ = Impact on Life
Questionnaire; MADR-S = Montgomery and Åsberg Depression Rating Scale; PHQ-9 = Patient Health Questionnaire-9; GDS-15 =
Geriatric Depression Rating Scale-15; GAD-7 = Generalized Anxiety Disorder-7; BADS-SF = Behavioral Activation for
Depression Scale – Short Form; Psi-Q = Plymouth Sensory Imagery Questionnaire; WHODAS-12 = WHO Disability Assessment
Schedule-12
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Table 2
Description of Studies - Behavioral Activation without a Values Component
Source/year

Treatment
Setting

Acierno et
al., 2012

Medical
University of
South
Carolina

Participants

Age

26 people
47who were
83
seeking
counseling
services
with
bereavement
issues
(22 women,
4 men)

Pre-Treatment/
Baseline Details

Treatment Details

Outcomes

Participants
were included if
they scored a 13
or higher on the
CGA and if they
have at least 1
risk factor for
CB.

Pilot trial testing BA-TE

Measured
using GAI,
PTSD &
MDD
symptom
count, BDI
& SF-36

BA-TE consists of
completing their daily
planner which consisted
of scheduling positively
& negatively reinforcing
behaviors and exposurebased behaviors.

Effect Size
BA-TE Effect
Sizes
GAI: 0.46
PTSD symptom
count: 0.41
MDD symptom
count: 0.38
BDI: 0.27
SF-36: 0.17
p-value<0.05

CritsChristoph
et al., 2021

Community
mental health
clinic in
Philadelphia

80 adults
seeking
services
who met
criteria

1865

Participants
were included if
they scored at
least an 11 on
the QIDS or met
DSM-V
diagnosis
criteria.

Control group (TAU) vs.
BA
BA was modeled off the
traditional manuscript.
The purpose is to
identify activities and
contexts that are
reinforcing and
consistent with an
individual’s long-term
goals. This is done
through self-monitoring,
structuring/scheduling
activities, rating degree

Measured
using
HAM-D,
BADS &
RPI

HAM_D
Effect size: 0.35
BADS
Effect size: -0.49
RPI
Effect size: -0.27
p-value<0.001
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of pleasure and
accomplishment
experienced.
TAU consisted of an
unspecified
psychotherapy.

Moradveisi
et al., 2014

Estupina
Puig, F. &
Labrador
Encinas, F.,
2012

Psychological 100 patients
service center with MDD
in Sanandaj,
(85 women)
Iran

University
Psychology
Clinic of
UCM

69 patients
with MDD

1860

1873

Participants
were included if
they had a
diagnosis of
MDD according
to the DSM-IVTR. This was
then confirmed
by the SCIDCT.

BA vs. ADM

The participants
were included if
they met DSM
criteria.

BA vs. CT vs. IT vs.
Clinic

The interviews
conducted were
semi-structured
using questions
from the BDI-II,
BAI and/or
SCL-90-R.

The BA intervention was
based off the traditional
manuscript. There were
16 sessions that occurred
over a 12-week period.

Measures
using
HRSD &
BDI-II

BA Effect Size
BDI: 0.24
HRSD: 0.20

The ADM intervention
was done by giving
sertraline to the group’s
participants.

The BA intervention
focused on problem
solving and social skill
training.
The CT intervention
focused on cognitive
restructuring and social
skill training.

ADM Effect Size
BDI: 0.19
HRSD: 0.09

p-value<0.001

Measured
using BDIII, BAI &
SCL

BA: 2.78
CT: 1.94
IT: 2.17
Clinic: 3.12
p-value<0.001
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The IT intervention
focused on coping with
bereavement loss, role
transitions, and other
interpersonal difficulties.
The Clinic’s intervention
used skills from all the 3
other intervention for
treatment.

Okajima, I.
& Chen, J.,
2017

Waseda
University,
Japan

49 adults

1865

Participants
were included if
scored a 55 or
higher on the
PSWQ*.

Control group vs. BAW
The BAW intervention
was modeled off the
traditional manuscript
but also focused on
functional assessments
of worry and improving
sleep hygiene.

Measured
BAW: 0.74
using ISI.,
Control: -0.23
PSWQ,
DASS,
p-value<0.01
CBAS, IUS
& WSAS

Note. Summaries of studies that used behavioral activation without a values component including the treatment setting, the
participant descriptions, the baseline and pre-screening measures, the treatment details, the outcome measures, and the effect size.
Effect sizes were determined by comparing pre-treatment and post-treatment scores.
Abbreviations: CGA = Comprehensive Geriatric Assessment; CB = Complicated Bereavement; BA-TE = Behavioral Activation
with Therapeutic Exposure; GAI = Generalized Anxiety Index; PTSD = Post Traumatic Stress Disorder; MDD = Major Depressive
Disorder; BDI = Beck’s Depression Inventory; SF-36 = Short Form Survey-36; QIDS = Quick Inventory of Depressive
Symptomatology; DSM-V/ DSM-IV-TR = Diagnostic and Statistical Manual of Mental Disorders, fifth edition/fourth edition, text
revision; TAU = Treatment As Usual; BA = Behavioral Activation; HAM-D/HRSD = Hamilton Depression Rating Scale; BADS =
Behavioral Activation for Depression Scale; RPI = Recovery Process Inventory; SCID-CT = Structured Clinical Interview for DSM
– Clinical Trial Version; ADM = Allen Diagnostic Module; UCM = Universidad Complutense de Madrid; CT = Cognitive Therapy;
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IT = Interpersonal Therapy; SCL/SCL-90-R = Symptom Checklist; BAI = Beck’s Anxiety Inventory; PSWQ = Penn State Worry
Questionnaire; BAW = Behavioral Activation for Worry; ISI = Insomnia Severity Index; DASS = Depression Anxiety Stress Scale;
CBAS = Cognitive-Behavioral Avoidance Scale; IUS = Intolerance of Uncertainty Scale; WSAS = Work and Social Adjustment
Scale
*This study defines clinical excessive worry as a transdiagnostic process across both anxiety and depression.

